HIGH TIDE INC (HITI.CA) Stock Fundamental Analysis
Canada - TSX-V:HITI - CA42981E4013 - Common Stock
5.5 CAD
+0.59 (+12.02%)
Taking everything into account, HITI scores 4 out of 10 in our fundamental rating. HITI was compared to 34 industry peers in the Pharmaceuticals industry. HITI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, HITI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
HITI had negative earnings in the past year.
In the past year HITI had a positive cash flow from operations.
HITI had negative earnings in each of the past 5 years.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
HITI's Return On Assets of -4.17% is in line compared to the rest of the industry. HITI outperforms 47.06% of its industry peers.
HITI has a Return On Equity (-6.91%) which is in line with its industry peers.
With an excellent Return On Invested Capital value of 4.75%, HITI belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROIC | 4.75% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 2.22%, HITI is doing good in the industry, outperforming 67.65% of the companies in the same industry.
HITI has a worse Gross Margin (25.83%) than 67.65% of its industry peers.
In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HITI is destroying value.
Compared to 1 year ago, HITI has more shares outstanding
HITI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HITI has been reduced compared to a year ago.
2.2 Solvency
HITI has an Altman-Z score of 4.54. This indicates that HITI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HITI (4.54) is better than 91.18% of its industry peers.
The Debt to FCF ratio of HITI is 4.52, which is a neutral value as it means it would take HITI, 4.52 years of fcf income to pay off all of its debts.
HITI has a better Debt to FCF ratio (4.52) than 82.35% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that HITI is not too dependend on debt financing.
HITI's Debt to Equity ratio of 0.30 is in line compared to the rest of the industry. HITI outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 4.54 |
ROIC/WACC0.53
WACC9.02%
2.3 Liquidity
A Current Ratio of 1.57 indicates that HITI should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.57, HITI is in line with its industry, outperforming 44.12% of the companies in the same industry.
A Quick Ratio of 0.97 indicates that HITI may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.97, HITI is doing worse than 61.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
HITI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -321.45%.
HITI shows a small growth in Revenue. In the last year, the Revenue has grown by 7.10%.
The Revenue has been growing by 75.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-321.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.71%
Revenue 1Y (TTM)7.1%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.9%
3.2 Future
HITI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 74.44% yearly.
HITI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.96% yearly.
EPS Next Y-6.88%
EPS Next 2Y83.38%
EPS Next 3Y93.9%
EPS Next 5Y74.44%
Revenue Next Year11.85%
Revenue Next 2Y16.73%
Revenue Next 3Y17.75%
Revenue Next 5Y14.96%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
HITI is valuated quite expensively with a Price/Forward Earnings ratio of 64.07.
Based on the Price/Forward Earnings ratio, HITI is valued a bit cheaper than the industry average as 70.59% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, HITI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 64.07 |
4.2 Price Multiples
64.71% of the companies in the same industry are more expensive than HITI, based on the Enterprise Value to EBITDA ratio.
HITI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. HITI is cheaper than 67.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.14 | ||
| EV/EBITDA | 14.51 |
4.3 Compensation for Growth
A more expensive valuation may be justified as HITI's earnings are expected to grow with 93.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y83.38%
EPS Next 3Y93.9%
5. Dividend
5.1 Amount
HITI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:HITI (9/18/2025, 7:00:00 PM)
5.5
+0.59 (+12.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners7.98%
Inst Owner ChangeN/A
Ins Owners8.81%
Ins Owner ChangeN/A
Market Cap478.94M
Analysts80
Price Target7.91 (43.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.69%
Min EPS beat(2)-11.37%
Max EPS beat(2)-8%
EPS beat(4)1
Avg EPS beat(4)-48.88%
Min EPS beat(4)-315.76%
Max EPS beat(4)139.6%
EPS beat(8)5
Avg EPS beat(8)27.56%
EPS beat(12)9
Avg EPS beat(12)32.7%
EPS beat(16)11
Avg EPS beat(16)20.33%
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.6%
Revenue beat(4)3
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.9%
Revenue beat(8)5
Avg Revenue beat(8)0.38%
Revenue beat(12)9
Avg Revenue beat(12)1.89%
Revenue beat(16)13
Avg Revenue beat(16)7.54%
PT rev (1m)3.33%
PT rev (3m)13.42%
EPS NQ rev (1m)80.02%
EPS NQ rev (3m)85.73%
EPS NY rev (1m)-21.22%
EPS NY rev (3m)-21.22%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)-0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 64.07 | ||
| P/S | 0.87 | ||
| P/FCF | 34.14 | ||
| P/OCF | 19.31 | ||
| P/B | 3.42 | ||
| P/tB | 9.68 | ||
| EV/EBITDA | 14.51 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.09
Fwd EY1.56%
FCF(TTM)0.16
FCFY2.93%
OCF(TTM)0.28
OCFY5.18%
SpS6.32
BVpS1.61
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROCE | 6.6% | ||
| ROIC | 4.75% | ||
| ROICexc | 5.86% | ||
| ROICexgc | 14.81% | ||
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 2.55% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 1.22 | ||
| Cap/Depr | 47.33% | ||
| Cap/Sales | 1.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 70.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 4.54 |
F-Score5
WACC9.02%
ROIC/WACC0.53
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-321.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.71%
EPS Next Y-6.88%
EPS Next 2Y83.38%
EPS Next 3Y93.9%
EPS Next 5Y74.44%
Revenue 1Y (TTM)7.1%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.9%
Revenue Next Year11.85%
Revenue Next 2Y16.73%
Revenue Next 3Y17.75%
Revenue Next 5Y14.96%
EBIT growth 1Y37.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year316.17%
EBIT Next 3Y105.72%
EBIT Next 5Y77.23%
FCF growth 1Y182.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y110.28%
OCF growth 3YN/A
OCF growth 5YN/A